ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4) is an enzyme that plays a critical role in determining whether cells are vulnerable to ferroptosis. While ACSL4 performs routine metabolic functions under normal conditions, its activity dramatically influences a cell’s susceptibility to iron-dependent cell death.

ACSL4 belongs to a family of five enzymes (ACSL1, 3, 4, 5, and 6) that activate long-chain fatty acids by attaching them to coenzyme A (CoA). This “activation” is necessary before fatty acids can be incorporated into membrane lipids, burned for energy, or used in signaling. Each family member has preferences for different fatty acids and serves distinct cellular functions.

What makes ACSL4 special is its strong preference for polyunsaturated fatty acids (PUFAs)—particularly arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4). These are the exact fatty acids that, when incorporated into membrane phospholipids, make cells vulnerable to lipid peroxidation and ferroptosis.

The Discovery of ACSL4’s Role in Ferroptosis

The connection between ACSL4 and ferroptosis emerged from genetic screens seeking to understand why some cells resist ferroptosis-inducing compounds. In 2016, multiple research groups made a striking discovery:

Kimberly Pratt and Joseph Witztum at UC San Diego, along with Scott Dixon at Stanford, found that cells lacking ACSL4 were highly resistant to ferroptosis. When they deleted or inhibited ACSL4, cells became virtually impervious to erastin, RSL3, and other ferroptosis inducers—even though GPX4 was still inhibited.

This was surprising. Scientists expected that GPX4 inhibition would inevitably cause ferroptosis, but ACSL4-deficient cells survived perfectly well. The reason: without ACSL4, cells couldn’t incorporate enough PUFAs into their membranes to generate the lipid peroxides that actually kill cells during ferroptosis.

How ACSL4 Promotes Ferroptosis

ACSL4 acts as a metabolic “gatekeeper” that controls membrane lipid composition:

Step 1: Fatty Acid Activation
ACSL4 takes free polyunsaturated fatty acids—particularly arachidonic acid and adrenic acid—and attaches them to CoA, creating acyl-CoA molecules. This activation is ATP-dependent and makes the fatty acids ready for the next step.

Step 2: Membrane Incorporation
The PUFA-CoA molecules are then used by other enzymes (particularly LPCAT3) to build phospholipids containing these polyunsaturated fatty acids. These phospholipids are inserted into cellular membranes.

Step 3: Creating Vulnerable Substrates
Phospholipids containing PUFAs—especially those with AA or AdA at the sn-2 position—are highly susceptible to oxidation. The multiple carbon-carbon double bonds in these fatty acids are chemically reactive sites where iron-catalyzed lipid peroxidation can occur.

Step 4: Ferroptosis Sensitivity
When GPX4 is inhibited or overwhelmed, these PUFA-containing phospholipids become oxidized (peroxidated). The resulting lipid hydroperoxides accumulate in membranes, disrupting membrane integrity and causing ferroptotic cell death.

Without ACSL4: Cells primarily incorporate monounsaturated or saturated fatty acids into their membranes. These lipids are far less susceptible to peroxidation, so even when GPX4 is inhibited, toxic lipid peroxides don’t accumulate to lethal levels.

ACSL4’s Substrate Specificity

ACSL4’s preference for specific PUFAs is crucial to its role:

Preferred Substrates:

• Arachidonic acid (AA, C20:4 n-6): The most abundant PUFA in many cell membranes and ACSL4’s favorite substrate
• Adrenic acid (AdA, C22:4 n-6): Another highly susceptible PUFA that ACSL4 efficiently activates
• Eicosapentaenoic acid (EPA, C20:5 n-3): An omega-3 PUFA that ACSL4 can also activate

Less Preferred:

• Oleic acid (C18:1): A monounsaturated fatty acid with only one double bond, far less susceptible to peroxidation
• Saturated fatty acids: Lacking double bonds, these are resistant to peroxidation

This substrate selectivity means ACSL4 activity directly determines how many “ferroptosis-vulnerable” lipids end up in cell membranes.

ACSL4 Expression and Localization

Cellular Location
ACSL4 localizes to several cellular membranes:

• Endoplasmic reticulum (ER): Where most phospholipid synthesis occurs
• Mitochondria-associated membranes (MAMs): Contact sites between ER and mitochondria
• Peroxisomes: Organelles involved in lipid metabolism

This distribution allows ACSL4 to supply PUFA-CoAs to different phospholipid synthesis pathways throughout the cell.

Tissue Expression
ACSL4 expression varies significantly across tissues and cell types:

• High expression: Steroidogenic tissues (adrenal glands, testes), certain regions of the brain, immune cells
• Variable expression: Many cancers show altered ACSL4 levels compared to normal tissue
• Low or absent: Some cell types naturally lack ACSL4 and are consequently ferroptosis-resistant

ACSL4 in Cancer

ACSL4’s role in ferroptosis makes it particularly relevant to cancer biology:

Ferroptosis-Sensitive Cancers
Certain cancers express high levels of ACSL4 and are consequently vulnerable to ferroptosis induction:

• Renal cell carcinoma: Often shows high ACSL4 expression
• Triple-negative breast cancer: Some subtypes have elevated ACSL4
• Diffuse large B-cell lymphoma: ACSL4 expression correlates with ferroptosis sensitivity
• Pancreatic cancer: Many pancreatic tumors express ACSL4

These cancers may be particularly good targets for ferroptosis-inducing therapies.

Resistance Through ACSL4 Loss
Some cancer cells evade ferroptosis by downregulating or losing ACSL4 expression:

• Cells can develop resistance to ferroptosis inducers by suppressing ACSL4
• Some tumors naturally lack ACSL4, making them intrinsically resistant
• ACSL4 loss can be a mechanism of acquired resistance to certain cancer therapies

Therapeutic Implications
ACSL4 expression status could serve as a biomarker to predict which tumors will respond to ferroptosis-inducing therapies. Testing tumor tissue for ACSL4 might help oncologists identify patients most likely to benefit from these treatments.

ACSL4 Beyond Ferroptosis

While ACSL4’s role in ferroptosis is now well-established, it serves other cellular functions:

Eicosanoid Synthesis
ACSL4 activates arachidonic acid for production of eicosanoids—signaling molecules including prostaglandins and leukotrienes involved in inflammation and immune responses.

Membrane Remodeling
ACSL4 contributes to maintaining membrane fluidity and function through its role in phospholipid composition.

Metabolic Signaling
PUFA-containing lipids generated through ACSL4 activity can serve as signaling molecules and influence cellular metabolism.

Regulation of ACSL4

Understanding what controls ACSL4 expression and activity is an active area of research:

Transcriptional Regulation
Various transcription factors can increase or decrease ACSL4 gene expression, though the full regulatory network is still being mapped.

p53 Connection
The tumor suppressor p53 has been shown to regulate ACSL4 expression in some contexts, linking ferroptosis to classic tumor suppression pathways.

Metabolic Signals
Cellular metabolic state, nutrient availability, and lipid levels can influence ACSL4 expression and activity.

Post-Translational Modifications
Phosphorylation and other modifications can alter ACSL4 activity, providing rapid regulation beyond changes in expression level.

ACSL4 in Disease

Neurological Disorders
ACSL4’s role in generating lipid peroxidation substrates may contribute to:

• Neurodegenerative diseases where ferroptosis is implicated
• Traumatic brain injury
• Stroke and ischemia-reperfusion damage

Cardiovascular Disease
ACSL4-driven lipid peroxidation may play roles in:

• Myocardial infarction (heart attack)
• Atherosclerosis
• Cardiac ischemia-reperfusion injury

Metabolic Disorders
ACSL4’s broader role in lipid metabolism connects it to:

• Fatty liver disease
• Metabolic syndrome
• Inflammatory conditions

Therapeutic Targeting of ACSL4

ACSL4 represents a potential therapeutic target from multiple angles:

Inhibiting ACSL4 to Prevent Ferroptosis
In diseases where ferroptosis causes tissue damage, ACSL4 inhibitors could:

• Reduce membrane PUFA content
• Decrease ferroptosis sensitivity
• Protect cells from iron-dependent damage

Challenges: ACSL4 inhibitors need to be selective (to avoid affecting other ACSL family members) and effective without disrupting essential fatty acid metabolism.

Exploiting ACSL4 in Cancer
In ACSL4-expressing tumors:

• Ferroptosis inducers may be particularly effective
• ACSL4 expression testing could guide treatment selection
• Combination therapies might prevent ACSL4 downregulation as a resistance mechanism

Working with LPCAT3: A Partnership

ACSL4 doesn’t work alone—it partners closely with LPCAT3 (lysophosphatidylcholine acyltransferase 3):

• ACSL4 activates the PUFA by making PUFA-CoA
• LPCAT3 takes that PUFA-CoA and incorporates it into phospholipids

Together, the ACSL4-LPCAT3 axis determines membrane PUFA content and ferroptosis sensitivity. Cells need both enzymes to be highly ferroptosis-sensitive; lacking either one provides protection.

Key Takeaways

ACSL4 is a metabolic enzyme with profound implications for cell fate:

• It determines which fatty acids get incorporated into membranes
• By preferring polyunsaturated fatty acids, it creates substrates for ferroptotic lipid peroxidation
• Its expression level predicts ferroptosis sensitivity
• It’s a potential therapeutic target in diseases involving ferroptosis
• It serves as a biomarker for ferroptosis-based cancer therapies

Understanding ACSL4 reveals how routine metabolic processes—specifically, which fatty acids cells choose to put in their membranes—can determine the difference between life and death. This enzyme sits at the intersection of lipid metabolism and cell death, making it a critical player in ferroptosis biology.